The chief executive of biotech Athira Pharma has permanently left the company after papers she published as a graduate student were found to contain altered research. Leen Kawas was suspended in June, after STAT asked the Alzheimer’s research company to comment on the allegations, and Athira announced her resignation as president, chief executive, and member of the board of directors today.
Mark Litton, the company’s chief operating officer, will take Kawas’ place to lead Athira.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
